ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0838

Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans

Tawnie Braaten1, shaobo Pei2, Anitha Rathod2, Gopi Penmetsa3, Kevin Douglas4, Jodi Walker4, Jerry Clewell5 and Jessica Walsh6, 1Salt Lake City Veteran Affairs and University of Utah Medical Center, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, 4AbbVie Inc., North Chicago, IL, 5Abbvie Inc, North Chicago, IL, 6Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT

Meeting: ACR Convergence 2021

Keywords: Access to care, Ankylosing spondylitis (AS), Psoriatic arthritis, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to identify baseline patient factors associated with treatment initiation during the 12 months after the initial diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS).

Methods: Active users of the Veteran Affairs Health System with an incident IA diagnosis between 1/1/2007 and 12/31/2019 were included (Figure 1). Data resources included the corporate data warehouse and the VA Informatics and Computing Infrastructure. Coded data were used to identify comorbidities, medications, laboratory data, provider visits and other encounters in the VA system. Natural language processing improved the accuracy of incident cohort identification and identifying erosions due to IA in the text of radiology reports. Treatment was captured during the 12 months following the initial IA diagnosis. Univariate analysis was used to explore patient factors associated with treatment. In normally distributed continuous variables means and standard deviations were compared, while medians and interquartile ranges were used for non-normally distributed variables.

Results: The study included 18,318 Veterans with incident IA (14,470 RA, 2380 PsA, 1468 AS). The mean age was 63.1 years and 90.7% were male. In the 12 month follow-up period, 40.7% did not use an IMM. VA system utilization was similar between groups (RR=1.000). Characteristics significantly associated with treatment included younger age (RR=0.9985), female gender (RR=0.9781), white race (RR=1.0179) non-Hispanic ethnicity (RR=1.0248), divorced marital status (RR=1.0118), and higher BMI (RR=1.0016). Estimates of socioeconomic status (measured by the area deprivation index [ADI]) were similar amongst patients with available data, but treatment was less frequent in patients with missing ADI (RR=1.0545). Higher comorbidity burden (RR=0.9883), alcohol dependence (RR=0.9718), heart failure (RR=0.9433), kidney disease (RR=0.9144), and osteoporosis (RR=0.9487) associated with non-treatment. Rheumatology (RR=1.2356), dermatology (RR=1.0462), gastroenterology (RR=1.0342), and orthopedic (RR=1.0232) visits were associated with treatment. Use of glucocorticoids (RR=1.1341), NSAIDS (RR=1.0785), and opiates (RR=1.0214) associated with treatment. Tests associated with therapy included: HLA-B27, RF, CCP, CRP, ESR. Positive results with RF, CCP, ESR, and articular erosions were associated with treatment (Table 2).

Conclusion: Several patient factors including certain demographics, subspecialty visits, additional medications, laboratory testing and erosions on imaging had a positive association with treatment. Other patient factors such as male gender, comorbidities and unknown addresses had a negative association with treatment. Future research with added analyses of these factors (multivariate analysis) and additional factors (health system and provider variables) may inform strategies to improve early treatment in appropriate patients with IA.

Figure 1: Attrition

Table 1: Associations between patient factors and immune modulating medications for inflammatory arthritis (univariate analysis)


Disclosures: T. Braaten, Gilead, 1; s. Pei, None; A. Rathod, None; G. Penmetsa, None; K. Douglas, AbbVie, 3, 11; J. Walker, Abbvie, 3; J. Clewell, Abbvie Inc, 3, 11; J. Walsh, AbbVie, 2, 5, Merck, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Eli Lilly, 1, 2, Novartis, 2, 5, Amgen, 2, 5.

To cite this abstract in AMA style:

Braaten T, Pei s, Rathod A, Penmetsa G, Douglas K, Walker J, Clewell J, Walsh J. Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/predictors-of-treatment-for-inflammatory-arthritis-with-immune-modulating-medications-imm-in-us-veterans/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-treatment-for-inflammatory-arthritis-with-immune-modulating-medications-imm-in-us-veterans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology